Publication Name	World Journal of Gastroenterology
Manuscript ID	5781
Country	Taiwan

Received	2013-09-25 21:51
Peer-Review Started	2013-09-27 08:18
To Make the First Decision	2013-12-26 10:56
Return for Revision	2013-10-16 14:33
Revised	2013-10-25 10:42
Second Decision	2014-01-15 20:21
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-01-15 20:37
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-03-01 18:10
Publish the Manuscript Online	2014-03-18 14:14

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection
Manuscript Source	Invited Manuscript
All Author List	Chun-Jen Liu and Pei-Jer Chen
Funding Agency and Grant Number	Funding Agency Grant Number National Taiwan University Department of Health, Executive Yuan, Taiwan Taiwan Liver Disease Consortium (TLC), National Research Program for Biopharmaceuticals (NRPB), Taiwan NSC100-2325-B-002-052
Corresponding Author	Pei-Jer Chen, MD, PhD, Distinguished Professor, Graduate Institute of Clinical Medicine, Department of Internal Medicine, and Hepatitis Research Center, National Taiwan University College of Medicine and National Taiwan University Hospital, Chang-Te Street, Taipei 10002, Taiwan. peijerchen@ntu.edu.tw
Key Words	Dual infection; Hepatitis B virus; Hepatitis C virus; Interferon; Pegylated interferon; Ribavirin; Sustained virological response; Hepatitis B surface antigen clearance
Core Tip	Patients with dual hepatitis C virus (HCV)/hepatitis B virus (HBV) infections have a higher risk of liver disease progression compared with patients with HBV or HCV monoinfections. The combination peginterferon alpha/ribavirin treatment for dual hepatitis patients with HCV dominance appears to be just as effective in the clearance of HCV RNA and safe as it is in patients with HCV monoinfections. The durability of HCV response was 97%. Furthermore, approximately 30% of dually infected patients lost hepatitis B surface antigen within 5 years after the start of peginterferon-based therapy. A population-based study revealed the benefits of combination therapy in the improvement of long-term outcomes in dually infected patients.
Publish Date	2014-03-18 14:14
Citation	Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol 2014; 20(11): 2955-2961
URL	http://www.wjgnet.com/1007-9327/full/v20/i11/2955.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i11.2955

Full Article (PDF)	WJG-20-2955.pdf
Full Article (Word)	WJG-20-2955.doc
Manuscript File	5781-Review.doc
Answering Reviewers	5781-Answering reviewers.pdf
Copyright License Agreement	5781-Copyright agreement.pdf
Non-Native Speakers of English Editing Certificate	5781-Language certificate.pdf
Peer-review Report	5781-Peer reviews.pdf
Scientific Editor Work List	5781-Scientific editor work list.doc